Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
Jaclyn Flanigan, Hari Deshpande, Scott GettingerYale Cancer Center/Yale University School of Medicine New Haven, CT, USAAbstract: Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 a...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2010-08-01
|
| Edice: | Biologics: Targets & Therapy |
| On-line přístup: | http://www.dovepress.com/current-status-of-vandetanib-zd6474-in-the-treatment-of-non-small-cell-a5138 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|